Science Corporation says it raised $400 million in Series D


Science Corporation says the Khosla Ventures-led round will help prepare a US launch for PRIMA. The company says the US Food and Drug Administration granted the retinal implant rare-condition status for patients blind in both eyes from advanced geographic atrophy caused by age-related macular degeneration, with no vision loss from another eye disease. US approval is still pending.
Sole source: Science Corporation said on 17 November 2026 that it raised $400 million in a Series D financing round led by Khosla Ventures. The medical technology company says the money will help it prepare to launch PRIMA in the US for patients with severe vision loss from advanced age-related macular degeneration. Science Corporation says it began selling the retinal implant system in Europe a few months before the round, after receiving the CE mark, which indicates conformity with European requirements.
Science Corporation named the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech among the other investors. Khosla Ventures and Y Combinator also took part in the earlier $230 million Series C.
The company says the round brought its total funding to more than $900 million since its founding in 2021. A person familiar with the deal told TechCrunch that investors valued the company at $3.5 billion. Science Corporation did not give a valuation in its financing announcement.
Science Corporation says it will also use the money to make PRIMA more widely available in Europe, expand its research, manufacturing and operations, and invest in a program that connects engineered nerve cells with the brain’s own circuits.
PRIMA is designed for patients with geographic atrophy, an advanced form of dry age-related macular degeneration. Patches of light-sensitive cells and supporting tissue in the retina die, permanently damaging the sharp central vision people use to read and recognize faces.

A camera on PRIMA’s glasses captures what is in front of the wearer. The glasses turn those images into patterns of near-infrared light and project them onto an implant under the retina. The implant stimulates surviving retinal cells to send visual signals to the brain, taking over some of the work of the lost cells.
The PRIMAvera trial implanted 38 patients. Science Corporation says the original results, published in The New England Journal of Medicine, showed that 80% of patients gained enough visual sharpness to read letters, numbers and words.
At 36 months, researchers could assess 27 participants for safety and only 18 for vision gains, limiting what the follow-up says about the full group. Science Corporation says 78% of those assessed for vision gains (14 people) improved by at least 15 letters on a standard eye chart using PRIMA. The company says serious adverse events were concentrated in the first 6 months after surgery, none were attributed to the device alone, and no new safety signal emerged between months 12 and 36.
Science Corporation says the US Food and Drug Administration (FDA) granted PRIMA a Humanitarian Use Device designation, which gives devices for rare conditions a faster review. Geographic atrophy itself is not rare, the company says, but the FDA accepted a narrower group: patients who are blind in both eyes from advanced geographic atrophy and have no vision loss from another eye disease.
The FDA still has to decide whether to grant a Humanitarian Device Exemption. That approval would let Science Corporation market PRIMA in the US and treatment centers use it for those patients. Science Corporation co-founder and CEO Max Hodak told Bloomberg he hoped PRIMA would reach US patients in early 2027, subject to FDA approval.
The watchdog found that some ads overstated links between common symptoms and low testosterone and that a Facebook ad’s claim it affects 25% of men over 30 lacked evidence. Voy says it won’t run the ads again.
3 min

Export value rose 20.5% from October 2025. Analysts say global investment in superintelligence (SI) helped sustain demand for Japanese chips and chipmaking equipment.
2 min

The study includes waste incinerators and finds that much of the 2040 total could be avoided with existing technology. It estimates 33–68 million metric tons of CO₂ could still need balancing through carbon removal to reach net zero in 2050.
3 min